# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Lake Street analyst Brooks O'Neil maintains Augmedix (NASDAQ:AUGX) with a Buy and lowers the price target from $8 to $3.5.
Maxim Group analyst Allen Klee downgrades Augmedix (NASDAQ:AUGX) from Buy to Hold.